|Articles|December 8, 2014
Sandoz's Biosimilar Shows Similarity to Amgen's Neupogen
Author(s)Agnes Shanley
Sandoz announces their version of filgrastim, a follow-on biologic for the treatment of neutropenia, is as safe and effective as Amgen's Neupogen.
Advertisement
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
How Big Biopharma Investment in CGTs Will Redefine the Industry Pipeline
2
Report - Digital Transformation in Biopharma: The Gap Between Hype and Implementation
3
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
4
Reducing CAR-T Manufacturing Times and Cost: Q&A with Trenchant’s Jon Ellis
5
